Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Items stated in the management plan
Partially revisedNet Sales+0.2%
基準 2,025Target2,030Hundreds of millions of yen
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
ROE13.5% (FY2025 actual results) → Not disclosed
Only the target level is shown because the current level for comparison was not provided.What happened to the previous planNot disclosed → STS Phase2 actual results through FY2025: revenue of ¥499.7 billion, overseas revenue CAGR of 15.2%, and EBITDA of ¥187.7 billion
Investment amount by sectorField Research and development costs / Amount ¥334 billion / Period Covered FY2023–FY2025, Field Business and capital investment / Amount ¥1.039 trillion / Period Covered FY2023–FY2025, Field Research and development costs / Amount ¥155 billion / Period Covered Fiscal 2026, Field Business and capital investment / Amount ¥720 billion / Period Covered Fiscal 2026
Statements about the use of capital
Payout ratio / DOE policySet a DOE target of 4% or higher. The basic policy is to increase the dividend for 15 consecutive fiscal years. The applicable period is not specified.The payout ratio is the proportion of profit paid out as dividends, while DOE is the ratio of dividends to net assets.
Treasury share acquisition policyThe Company will conduct flexible share repurchases depending on its investment conditions and market conditions. Share repurchases totaled ¥75 billion during fiscal years 2023-2025.
Self-assessment of PBR and share pricePBR was 1.8x in FY2025. PER has remained stagnant, and the Company aims to improve its PER and PBR by communicating initiatives designed to raise future expectations.PBR is a measure of how many times the share price is the book value per share.
Key initiatives
01Expansion of Overseas Operations
02Expand products other than prescription pharmaceuticals
03Provide new platform services
04Upgrade corporate functions
05Strengthening the Business Foundation
06Strengthening Human Resources
07Advance digital transformation
08Strengthening Risk Management
09Strengthening the management platform
10Strengthen dialogue with investors
Non-financial targetsIndicator name In-house drug-discovery ratio / Target value Maintain an in-house drug-discovery ratio above 60% / Timing Not specified
Risks identified by the company
Geopolitical and geo-economic risks
Risks in business execution
Risks with a significant impact on management
Risks arising from changes in the business environment
| Item | Details |
|---|---|
| Plan name | STS2030 Revision |
| Progress against the plan | Partially revised |
| Sales Target | ¥499.7 billion (STS Phase2 actual results through FY2025) → ¥800 billion (STS2030 Revision target) |
| ROE target | 13.5% (FY2025 actual results) → Not disclosed |
| Payout ratio / DOE policy | Set a DOE target of 4% or higher. The basic policy is to increase the dividend for 15 consecutive fiscal years. The applicable period is not specified. |
| Treasury share acquisition policy | The Company will conduct flexible share repurchases depending on its investment conditions and market conditions. Share repurchases totaled ¥75 billion during fiscal years 2023-2025. |
| Self-assessment of PBR and share price | PBR was 1.8x in FY2025. PER has remained stagnant, and the Company aims to improve its PER and PBR by communicating initiatives designed to raise future expectations. |
| Investment amount by sector | Field Research and development costs / Amount ¥334 billion / Period Covered FY2023–FY2025, Field Business and capital investment / Amount ¥1.039 trillion / Period Covered FY2023–FY2025, Field Research and development costs / Amount ¥155 billion / Period Covered Fiscal 2026, Field Business and capital investment / Amount ¥720 billion / Period Covered Fiscal 2026 |
| Non-financial targets | Indicator name In-house drug-discovery ratio / Target value Maintain an in-house drug-discovery ratio above 60% / Timing Not specified |
| Key initiatives | Expansion of Overseas Operations, Expand products other than prescription pharmaceuticals, Provide new platform services, Upgrade corporate functions, Strengthening the Business Foundation, Strengthening Human Resources, Advance digital transformation, Strengthening Risk Management, Strengthening the management platform, Strengthen dialogue with investors |
| Results under the previous plan | Not disclosed → STS Phase2 actual results through FY2025: revenue of ¥499.7 billion, overseas revenue CAGR of 15.2%, and EBITDA of ¥187.7 billion |
| Risks identified | Geopolitical and geo-economic risks, Risks in business execution, Risks with a significant impact on management, Risks arising from changes in the business environment |
| Date of board resolution | 24 June 2026 |
| Publication date | 24 June 2026 |
Items this document does not state (11)
Plan periodOperating profit targetOperating profit margin targetNet income targetROIC targetCost of capitalTotal investment planSegment targetPlan assumptionsReason for revision or withdrawalSize of the Target Market
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company's high drug-discovery capabilities, supported by a focus on specific fields, underpin strong royalty and domestic and overseas infectious disease businesses, contributing to a high ROE, while its PER has remained stagnant. The Company intends to improve its PER and PBR by communicating initiatives designed to raise expectations for future growth.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.